再生元制药公司披露，最新达成的协议条款中，除了已公布的核心内容外，还包含了价值约22亿美元的额外潜在里程碑付款。
此外，协议还设定了分级结构的特许权使用费安排，该安排将根据未来产品的商业化表现或特定销售目标的达成情况而动态调整。
这些财务条款的加入，显著提升了此次交易的整体潜在价值，并体现了合作方对相关研发项目商业化前景的共同信心。
再生元制药公司披露，最新达成的协议条款中，除了已公布的核心内容外，还包含了价值约22亿美元的额外潜在里程碑付款。
此外，协议还设定了分级结构的特许权使用费安排，该安排将根据未来产品的商业化表现或特定销售目标的达成情况而动态调整。
这些财务条款的加入，显著提升了此次交易的整体潜在价值，并体现了合作方对相关研发项目商业化前景的共同信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.